成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

返回ChemicalBook首頁(yè)>CAS數(shù)據(jù)庫(kù)列表>66515-29-5

66515-29-5

中文名稱(chēng) MSOP
英文名稱(chēng) MSOP
CAS 66515-29-5
分子式 C4H10NO6P
分子量 199.1
MOL 文件 66515-29-5.mol
66515-29-5 結(jié)構(gòu)式 66515-29-5 結(jié)構(gòu)式

基本信息

中文別名
2-甲基-O-磷酸絲氨酸
英文別名
MSOP
2-Methyl-O- phosphonoserine
Serine, 2-methyl-O-phosphono-
(RS)-α-Methylserine-O-phosphate
(R,S)-a-Methylserine-O-phosphate
(RS)-ALPHA-METHYLSERINE-O-PHOSPHATE

物理化學(xué)性質(zhì)

沸點(diǎn)454.0±55.0 °C(Predicted)
密度1.681±0.06 g/cm3(Predicted)
儲(chǔ)存條件Store at RT
溶解度在水中的溶解度為性3mg/mL,澄清(加熱)
酸度系數(shù)(pKa)1.66±0.10(Predicted)
形態(tài)粉末
顏色白色至米色
水溶解性溶于水至100mM

安全數(shù)據(jù)

危險(xiǎn)性符號(hào)(GHS)GHS hazard pictograms
GHS06
警示詞危險(xiǎn)
危險(xiǎn)性描述H301
防范說(shuō)明P301+P310
危險(xiǎn)品標(biāo)志T
危險(xiǎn)類(lèi)別碼25
安全說(shuō)明45
危險(xiǎn)品運(yùn)輸編號(hào)UN 2811 6.1 / PGIII
WGK Germany3
MSOP價(jià)格(試劑級(jí))
報(bào)價(jià)日期產(chǎn)品編號(hào)產(chǎn)品名稱(chēng)CAS號(hào)包裝價(jià)格
2025/05/22HY-101226MSOP66515-29-51 mg1400元
2025/05/22HY-101226MSOP
MSOP
66515-29-55mg2900元
2025/05/22HY-101226MSOP66515-29-510 mg4600元

常見(jiàn)問(wèn)題列表

生物活性
MSOP 是第三組代謝性谷氨酸受體的選擇性拮抗劑,其對(duì) L-AP4 敏感突觸前代謝性谷氨酸受體的 KD 值為 51 μM。
靶點(diǎn)

K D : 51 μM (L-AP4-sensitive presynaptic mGluR).

體外研究

In the presence of 200 μM MSOP, a rightward parallel shift of the dose-response curve to L-AP4 is observed, with an apparent K D calculated as 51±6 μM (n=3). MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR, the apparent K D for the interaction of MSOP with the (1S, 3S)-ACPD sensitive receptor calculated as greater than 700 μM (n=3).

體內(nèi)研究

It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F 3,16 =30.96, P<0.001; CFA model: F 3,16 =30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group.

"66515-29-5" 相關(guān)產(chǎn)品信息